A Study of Possibility of Using Regulatory T Cells(VT301) for Treatment of Alzheimer's Disease
Phase 1
- Conditions
- Alzheimer Disease
- Interventions
- Biological: VT301
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- VTBIO Co. LTD
- Target Recruit Count
- 12
- Registration Number
- NCT05016427
- Locations
- 🇰🇷
Vtbio Co., Ltd, Seoul, Korea, Republic of
Double Blinded, Randomized, Placebo-controlled Clinical Study for Nelumbinis Semen
Not Applicable
Completed
- Conditions
- Stress
- Interventions
- Dietary Supplement: PM011
- First Posted Date
- 2019-06-04
- Last Posted Date
- 2019-06-04
- Lead Sponsor
- VTBIO Co. LTD
- Target Recruit Count
- 46
- Registration Number
- NCT03973099
A Safety and Tolerability Study of GB301
Phase 1
- Conditions
- Alzheimer Disease
- Interventions
- Other: SalineBiological: Regulatory T cells
- First Posted Date
- 2019-03-06
- Last Posted Date
- 2019-08-05
- Lead Sponsor
- VTBIO Co. LTD
- Target Recruit Count
- 20
- Registration Number
- NCT03865017
- Locations
- 🇦🇺
Bht Lifescience Australia Pty Ltd, Brisbane, Queensland, Australia
Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease
Phase 2
Completed
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: PM012Drug: Placebo
- First Posted Date
- 2012-10-26
- Last Posted Date
- 2016-04-18
- Lead Sponsor
- VTBIO Co. LTD
- Target Recruit Count
- 151
- Registration Number
- NCT01715350
- Locations
- 🇰🇷
Kyung Hee University Oriental Medicine Hospital, Seoul, Dongdaemun-gu, Korea, Republic of
🇰🇷The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Seocho-gu, Korea, Republic of
🇰🇷National Health Insurance Corporation Ilsan Hospital, Goyang, Ilsandong-gu, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath